AIDS | Page 58 of 67 | SpiritIndia.com

HIV :: Virco introduces an improved rapid methodology to establish new hiv-1 resistance profiles

Responding to the need to make timely evaluations and decisions when treating treatment experienced HIV patients, Virco (http://www.vircolab.com), a leader in drug resistance testing recently introduced an improved virco(R)TYPE HIV-1 test that rapidly determines the complex phenotypic resistance profiles for darunavir, tipranavir and other antiretroviral (ARV) drugs. Utilizing clinical trial data that was used to support the approval of darunavir and tipranavir, virco(R)TYPE HIV-1 reports now include Clinical Cut-Offs (CCOs) for these recently introduced agents(1). Virco(R)TYPE HIV-1 analyzes patient HIV-1 resistant genotypes using Virco’s large database to quickly and accurately predict phenotypic resistance. This timely determination of phenotypic resistance assists physicians in choosing a drug treatment plan that has the least amount of drug resistance.

HIV :: HIV exploits competition among t-cells

A new HIV study shows how competition among the human immune system’s T cells allows the virus to escape destruction and eventually develop into full-blown AIDS. The study, which employs a computer model of simultaneous virus and immune system evolution, also suggests a new strategy for vaccinating against the virus – a strategy that the computer simulations suggest may prevent the final onset of AIDS.

Smallpox :: Mass vaccination unnecessary in the event of a large bioterrorist US smallpox attack

Mass vaccination would not be necessary in the event of a large-scale smallpox bioterrorist attack in the United States, according to a study led by researchers at Fred Hutchinson Cancer Research Center that appears online in the International Journal of Infectious Diseases.

HIV :: NIAID Announces New Campaign To Raise Awareness of Preventive HIV Vaccine Research

The National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, today announced the launch of the ?Be The Generation? public awareness campaign, challenging young Americans to be the generation that ends AIDS through the discovery of a safe and effective preventive HIV vaccine.

HIV :: Human genome sciences reports positive results of ccr5 mab in hiv-1

Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that the results of a Phase 1 clinical trial of HGS004 (CCR5 mAb) demonstrate that it was well tolerated and exhibited antiviral activity in patients who are infected with HIV-1, the retrovirus that causes acquired immunodeficiency syndrome (AIDS). The results were reported in San Francisco in an oral presentation at the American Society for Microbiology’s 46th Annual Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

Health :: Reduce Methamphetamine Abuse

New research supported in part by the National Institute on Drug Abuse (NIDA), National Institutes of Health, shows that prevention programs conducted in middle school can reduce methamphetamine abuse among rural adolescents years later. Because methamphetamine addiction leads to problems with social interactions and a wide range of medical conditions, research into early interventions such as this is critical to protecting the nation?s youth. The paper is published in the September issue of Archives of Pediatrics and Adolescent Medicine.

HIV :: HIV therapy drugs reach one in five-study

Only one in five people with HIV in poor and middle-income countries receives the drugs that treat the virus, said a report by the U.S. Centers for Disease Control and Prevention on Thursday.

HIV :: New Generic AIDS Drug for AIDS Relief

The Food and Drug Administration (FDA) today announced the tentative approval of generic abacavir (a-BAK-a-veer) sulfate tablets manufactured by Aurobindo Pharma LTD. of Hyderabad, India. Abacavir sulfate tablets are the first generic version of the already approved Ziagen Tablets, an anti-HIV medication manufactured by GlaxoSmithKline. This product will now be available for consideration for purchase under the President’s Emergency Plan for AIDS Relief.

HIV :: U.S. President George Bush ignores HIV prevention methods that work!

Who is informing the president on HIV and AIDS?

Fibromyalgia :: Fibromyalgia and Chronic Myofascial Pain – A Survival Manual

The original edition of this classic survival manual offered the first comprehensive patient guide for managing these conditions. Its extensive set of healing tools included targeted bodywork for painful trigger points and strategies to helpccope with chronic pain and sleep problems and the numbing effects of fibrofog.